Clinical Trials
9 trialsNCT07493304 2026-05-29
ROXI-CAT-II
Regeneron Pharmaceuticals
Phase 3 Recruiting
NCT06886516 2026-04-15
Apixaban in Thrombocytopenia
Beth Israel Deaconess Medical Center
Phase EARLY_PHASE1 Recruiting
NCT05171049 2026-02-23
ASTER
Anthos Therapeutics, Inc.
Phase 3 Terminated
NCT07270263 2025-12-26
HEM-DOAC
Medical University of Gdansk
Phase NA Recruiting
NCT03080883 2025-05-18
Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy
Academic and Community Cancer Research United
Phase 3 Completed
NCT02744092 2023-10-03
CANVAS
Alliance Foundation Trials, LLC.
Phase NA Completed
NCT04191928 2021-12-23
PAP-UP
Thomas Jefferson University
Phase 1 Completed
NCT02585713 2020-08-04
Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism
Academic and Community Cancer Research United
Phase 3 Completed
NCT00320255 2016-08-16
A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced (Metastatic) Cancer
Bristol-Myers Squibb
Phase 2 Completed